{"summary":"As a senior chemist at Lonza, I support our small molecule (API \/ HPAPI) and ADC platform offerings of Lonza, working with large and small pharmaceutical companies to benefit patients around the world. With over a decade of experience in pharmaceutical chemistry, I strive to support customers at all clinical stages from early development, to process optimization, process qualification\/validation and commercial supply.\n\nI currently manage a team of highly experienced technicians. Our work centers on highly complex, chemically challenging multi-step sequences for producing APIs as well as payloads\/drug linkers in ADCs, in addition to R&D and technology transfers. We work to introduce innovative processes to address drug delivery issues and help lower risk, improve costs and shorten development timelines for developing life-improving therapeutics.","lastName":"Noti","objectUrn":"urn:li:member:332926425","geoRegion":"Bern, Berne, Switzerland","fullName":"Christian Noti","firstName":"Christian","currentPositions":[{"companyName":"Lonza","description":"- Manage a team of seven highly experienced technicians\n- Manage R&D and technology transfers of highly complex, chemically challenging multi-step sequences for producing APIs as well as payloads\/drug linkers in ADCs \n- Lead the brainstorming team for introducing innovative processes to address the delivery issues or significantly improve the cost of goods\n- Perform evaluations\/costings\/establishing proposals and execution of multi-million-dollar R&D\/production programs especially in the HPAPI area\n- Deep understanding of GMP\/quality\/analytical aspects in the NCE\/small molecule segment\n- Strong collaboration with cross-functional teams e.g. analytical development, QC, logistics, QA, legal, sourcing","title":"Team Leader, API Development Services & HPAPI Lab Manufacturing","companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"country":"Switzerland","city":"Basel","postalCode":"4002","line1":"Muenchensteinerstr. 38"},"website":"http:\/\/www.lonza.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/lonza\/","industry":"Pharmaceutical Manufacturing"},"companyUrn":"urn:li:fs_salesCompany:7462","tenureAtCompany":{"numYears":15,"numMonths":9},"startedOn":{"month":7,"year":2018}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)","projects":[],"contactInfo":{"websites":[{"$anti_abuse_annotations":[{"attributeId":97,"entityId":19,"sourceUrn":"urn:li:member:332926425"},{"attributeId":48,"entityId":19,"sourceUrn":"urn:li:member:332926425"}],"category":"PERSONAL","dataSource":"LINKEDIN","url":"linkedin.com\/in\/ChristianNoti"}]},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2008},"degree":"Postdoc","eduId":213549791,"schoolUrn":"urn:li:fs_salesSchool:4522","school":"urn:li:fs_salesSchool:4522","schoolName":"University of Cambridge","startedOn":{"year":2007}},{"endedOn":{"year":2007},"degree":"Doctor of Philosophy (Ph.D.)","eduId":213549772,"schoolUrn":"urn:li:fs_salesSchool:4923","school":"urn:li:fs_salesSchool:4923","fieldsOfStudy":["Organic Chemistry"],"schoolName":"ETH Z\u00fcrich","startedOn":{"year":2003}},{"endedOn":{"year":2003},"degree":"Dipl. Chem. ETH (Diploma in Chemistry; MSc equivalent)","eduId":694149630,"schoolUrn":"urn:li:fs_salesSchool:4923","school":"urn:li:fs_salesSchool:4923","fieldsOfStudy":["Organic Chemistry"],"schoolName":"ETH Z\u00fcrich","startedOn":{"year":1997}}],"skills":[{"numOfEndorsement":4,"name":"Organic Chemistry"},{"numOfEndorsement":3,"name":"Product Development"},{"numOfEndorsement":2,"name":"Product Launch"},{"numOfEndorsement":2,"name":"GMP"},{"numOfEndorsement":1,"name":"Validation"},{"numOfEndorsement":1,"name":"Lifesciences"},{"numOfEndorsement":0,"name":"FDA"},{"numOfEndorsement":3,"name":"R&D"},{"numOfEndorsement":1,"name":"Pharmaceutical Industry"},{"numOfEndorsement":7,"name":"Chemistry"},{"numOfEndorsement":1,"name":"Technology Transfer"},{"numOfEndorsement":0,"name":"Biopharmaceuticals"},{"numOfEndorsement":0,"name":"Chromatography"},{"numOfEndorsement":0,"name":"Purification"},{"numOfEndorsement":0,"name":"HPLC"},{"numOfEndorsement":0,"name":"LIMS"},{"numOfEndorsement":0,"name":"Analytical Chemistry"},{"numOfEndorsement":0,"name":"UV\/Vis"},{"numOfEndorsement":0,"name":"LC-MS"},{"numOfEndorsement":0,"name":"Mass Spectrometry"}],"numOfConnections":706,"patents":[{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)"}],"title":"Noti C, Jackson B, Hu G,  \u201ePreparation of 3,5-dioxo hexanoate ester\"","issuer":"ch"},{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)"}],"title":"Noti C, Franzen M, \"Process for the preparation of (1s,4r)-2-oxa-3-azabicyclo[2,2.1]hept-5-enes\"","issuer":"ch"}],"headline":"Team Leader, API Development Services & HPAPI Lab Manufacturing bei Lonza","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/christiannoti","organizations":[],"location":"Bern, Berne, Switzerland","publications":[{"name":"Roberge DM, Noti C, Irle E, Eyholzer M, Rittiner B, Penn G, Sedelmeier G, Schenkel B, \u201eControl of Hazardous Processes in Flow: Synthesis of 2-Nitroethanol\u201d J. Flow Chem. 2013, 4, 26.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)"}]},{"name":"Castro V, Noti C, Chen W, Cristau M, Livignston A, Rodr\u00edguez H, Albericio F: \u201eNovel Globular Polymeric Supports for Membrane-Enhanced Peptide Synthesis\u201d Macromolecules 2017, 50, 1626.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)"}]},{"name":"Tiberghien AC, von Bulow C,  Barry C,  Ge H, Noti C, Leiris CF, McCormick M , Howard PW, Parker JS: \u201eScale-up Synthesis of Tesirine\u201d, Org. Process Res. Dev. 2018, 22, 1241.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABPYDdkBwKa8EbTp4X-JEnMMsZcS1tetsLs,NAME_SEARCH,wOQ1)"}]}],"positions":null,"posts":[{"createdAt":1713166680000,"insightId":"0d1a0709-a519-40f6-a35e-4c6a5eee1071","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQGuu1FkEhffDw\/image-shrink_1280\/0\/1713166680080?e=1717977600&v=beta&t=_QxFcp8ThJKhmFmbWAtxjKwXWFiFtJp5FTv8WFl1yZs"}},"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7185541862030503936","threadUrn":"urn:li:activity:7185541862030503936","reactionsCount":0,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7185541861313249280","message":{"attributes":[{"start":536,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/ekxFrqHJ"}}}],"text":"Drawing on our global survey, we examined the relationship between age groups and oral dosage forms. \n\nAge Group 30-39 years old: This segment stands out for its commitment to informed decision-making regarding supplements and medications. This demographic actively seeks additional product information, and demonstrates the highest spending and willingness to invest in premium features. Additionally, they report an increase in dosage form consumption across various use cases.\n\nFor a deeper dive of our survey's insights click here: https:\/\/lnkd.in\/ekxFrqHJ\n"},"entityUrn":"urn:li:share:7185541861313249280"}}},{"createdAt":1712840700000,"insightId":"1179676e-0ae4-4b82-b818-22ca666b9d18","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQE9qhMHXoh8PQ\/image-shrink_1280\/0\/1712840712186?e=1717977600&v=beta&t=HBlfiK-YCOO0yOTeFCgYexb8yOlttDGAYz0XSnm2lQk"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7184174658999439360","threadUrn":"urn:li:activity:7184174658999439360","reactionsCount":1,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184174652330541057","message":{"attributes":[{"start":0,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:dyk"}}},{"start":671,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eMHsdpn5"}}}],"text":"#DYK In the Asia Pacific region, approx 1 in 3 consumers want to address their joint health as it affects their mobility & ability to perform basic tasks. This clearly highlights the need for joint health supplements with proven results in joint flexibiity and mobility. \n\nStep in UC-II\u00ae. As the most researched brand of undenatured type II collagen, UC-II\u00ae collagen is clinically studied for joint health and mobility. In fact it is the only joint ingredient clinically proven to significantly improve joint flexibility\u201415 times better than placebo \u2014and help joints feel 10 years younger. \n\nRead about this exciting ingredient today!\n\nClick to download our e-book -- > \nhttps:\/\/lnkd.in\/eMHsdpn5\n"},"entityUrn":"urn:li:share:7184174652330541057"}}},{"createdAt":1710926580000,"insightId":"0f6adb54-3e5c-4478-b268-e44b6b83d920","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQHMvccOaKMBCQ\/image-shrink_1280\/0\/1710926622749?e=1717977600&v=beta&t=tTAbkCuI43NnH4mMHyZoBgC538VUE61tu_t66n58cy8"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":7}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7176146380816560130","threadUrn":"urn:li:activity:7176146380816560130","reactionsCount":7,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7176146380053172224","message":{"attributes":[{"start":496,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/egqDmxAx"}}},{"start":522,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:smlonza"}}},{"start":531,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:weworkasone"}}},{"start":544,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:smallmolecules"}}},{"start":560,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:microdosing"}}},{"start":573,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:webinar"}}}],"text":"My Lonza Tampa colleagues Mark Cappucci and Benito Graniela are giving a webinar where they\u2019ll describe how microdosing can accelerate a drug\u2019s journey through the development process. They\u2019ll also give an insight into how the Tampa team go about filling powder directly into capsules, giving dosage forms in multiple strengths.\n\nI\u2019m really looking forward to watching the webinar. It\u2019s taking place at 11am EDT\/4pm CET on Tuesday 26 March, and if you\u2019d like to watch too, you can register here: https:\/\/lnkd.in\/egqDmxAx\n\n#SMLonza #Weworkasone #smallmolecules #microdosing #webinar\n"},"entityUrn":"urn:li:share:7176146380053172224"}}},{"createdAt":1710144180000,"insightId":"5cc4e0f5-df40-4710-b9ca-cf4f50472341","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"VIDEO","thumnailUrl":"https:\/\/dms.licdn.com\/playlist\/vid\/D4E05AQHvt6UgCqQOHg\/videocover-firstframe-low\/0\/1710144201823?e=1717977600&v=beta&t=ag433xMyr2vO6HFYCUexZQjFDnHJsWCNV7wnBWi_r4E"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":9},{"type":"PRAISE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7172864704610979841","threadUrn":"urn:li:ugcPost:7172864704610979841","reactionsCount":10,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7172864704610979841","message":{"attributes":[{"start":449,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eK3q3DRV"}}}],"text":"Here at Lonza, we recently launched a new physiologically based pharmacokinetic (PBPK) service. It combines our in vitro tools with GastroPlus software from Simulations Plus to make predictions that help mitigate absorption risks in early stage drug development. On March 12, you can watch my colleague Deanna Mudie and John DiBella of Simulations Plus explain how it all works in a webinar. \n\nThe webinar is free, and you can register for it here: https:\/\/lnkd.in\/eK3q3DRV\n"},"entityUrn":"urn:li:ugcPost:7172864704610979841"}}}]}